BioCryst Stock Price Skyrocketted

BioCryst(BCRX), maker of H5N1 or bird flu related drug, seen its stock price up 3 dollar per share or 28% to $15.11 on the news that Roche Holding, Tamiflu producer, licensed an experimental compound from BioCryst for organ transplant rejection and auto-immune diseases although the compound is still in the early stage of experienment.